BefejeződöttFázis nélkül
Controlled Arterial Protection to Ultimately Remove Embolic Material
A legfontosabb adatok
- Ki végzi
- EmStop Inc
- Hol
- Asheville és Nashville (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 15 fő vett részt
- Kezdés
- 2023. dec. 27.
- Befejezés
- 2024. okt. 14.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- The EmStop Embolic Protection System (EmStop System)
- A regiszteradat frissítve
- 2025. április 29.
Ki vehet részt
- Életkor
- 21 év – 90 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Clinical \& Angiographic Inclusion Criteria
- Between 21 and 90 years of age at the time of consent
- Meets FDA approved indications for transcatheter aortic valve replacement (TAVR) procedure on a native aortic valve using a commercially available Abbott or Medtronic transcatheter heart valve
- Willing and able to provide written informed consent and written HIPAA authorization prior to initiation of study procedures
- Willing and able to comply with the protocol-specified procedures and assessments
- Subject anatomy is compatible with correct device deployment and positioning with:; Ability to achieve access with a 21 French equivalent femoral access sheath; Ascending aorta length ≥8 cm; Ascending aorta/aortic arch diameter is ≥25 or ≤40 mm; Ascending aorta or aortic arch exhibits ≤ Grade 1 atheromatous disease and limited wall calcification
Ki nem vehet részt
- Previously implanted aortic or mitral valve bioprosthesis
- Planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 30 days prior to the TAVR procedure. NOTE: Diagnostic cardiac catheterization is permitted up until baseline MRI is obtained. Once baseline MRI is obtained, no additional intra-aortic or intracardiac procedure may occur
- Documented history of stroke or TIA within the prior 6 months, or any prior stroke with a permanent major disability or deficit (NIHSS >1 at baseline)
- History of intolerance, allergic reaction, or contraindication to any of the study medications, including heparin, aspirin, clopidogrel, or a sensitivity to contrast media or anesthesia that cannot be adequately pre-treated
- Currently participating in another drug or device clinical study
- Hepatic failure (Child-Pugh class C)
- Acute myocardial infarction within 30 days of the planned index procedure
- Known allergy or sensitivity to nickel-titanium
- History of bleeding diathesis or a coagulopathy
- Renal failure, defined as estimated glomerular filtration rate (eGFR) <30 mL/min
- Left ventricular ejection fraction ≤30% within 3 months prior to procedure
- Active endocarditis or ongoing systemic infection, defined as fever (>38°C) and/or white blood cell (WBC) >15,000 IU
- Known or suspected to be pregnant, or is lactating; female subjects of child-bearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the index study procedure
- Requires urgent or emergent TAVR procedure
- Contraindicated to MRI
- Hypercoagulable state that cannot be corrected by additional periprocedural heparin
- Undergoing therapeutic thrombolysis
- Any other clinical reason, as deemed by the investigators of the study, by which the patient would not be an appropriate candidate for the study
- Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)
Helyszínek itt: Egyesült Államok
- Mission HealthAsheville, Egyesült Államok
- Centennial Medical CenterNashville, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of this study is to demonstrate device feasibility, safety and investigate performance of the EmStop Embolic Protection System when used as indicated in 15 subjects at 2 investigational sites in the U.S.
A vizsgálat csoportja
- EmStop Embolic Protection SystemA vizsgált kezelés
Transcatheter aortic valve replacement (TAVR) procedures with the EmStop Embolic Protection System (EmStop System).
Kezelés: The EmStop Embolic Protection System (EmStop System)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2025. április 29.